Call Spread on DHR on 1/3/2022

Danaher Corporation (DHR) designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions.

The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers.

The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings.

The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products.

The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Please note, this stock reports earnings on Thursday, January 27th.

Danaher reported 3rd Quarter September 2021 earnings of $2.39 per share on revenue of $7.2 billion. The consensus earnings estimate was $2.14 per share on revenue of $7.0 billion. Revenue grew 22.9% on a year-over-year basis.

The company said it expects fourth quarter revenue of approximately $7.44 billion to $7.071 billion. The current consensus revenue estimate is $7.61 billion for the quarter ending December 31, 2021.

With earnings beat in its last three quarters, this stock should see also follow another strong earnings report. Its fundamentals suggest that demand for testing in its Dagnostics department and equipment in its Environmental & Applied Solutions department.

Last Trade: $329.01

Trading Range: $211.22 - $333.96

Trade Buy 1 February $330.00 Call at $7.53 Sell 1 February $345.00 Call at $2.24 For a net debit of $5.29 Profit/Loss Analysis Breakeven at $335.29 Maximum profit is $971.00 at strike of $345.00 Maximum loss is ($529.00) at strike of $330.00 Closing Summary Sold 1 February $330.00 Call at $0.00 Bought 1 February $345.00 Call at $0.00

Position closed on 2/14/2022 at price of $0.00 with a -100.00% loss in 42 days.

Back to Portfolio